Finally, pharmaco–metabolomics studies indicated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, particularly that liraglutide treatment led to changes in the lipid metabolism involving sphingolipids, including ceramides that are suggestive of a lower risk of atherosclerosis and cardiovascular diseases (CVD) [27,28]. This evidence concerns the gene GLP1R and cardiovascular disorder.